Q32 Bio Prices $200 Million Public Stock Offering
Biotechnology firm Q32 Bio announced the pricing of a public offering of common stock and pre-funded warrants, expecting to raise approximately $200 million. Proceeds are earmarked for working capital and advancing clinical development.
Q32 Bio Inc., a clinical-stage biotechnology company, announced on July 14, 2026, the pricing of a public offering of its common stock and pre-funded warrants. The offering is expected to generate gross proceeds of approximately $200 million before deducting underwriting discounts and expenses. The company plans to use the net proceeds for working capital, including research, clinical development, and commercialization efforts.
The offering consists of approximately 6 million shares of common stock and nearly 5 million pre-funded warrants. Underwriters have been granted a 30-day option to purchase up to an additional 1.6 million shares. The transactions are expected to close on or about July 16, 2026, subject to customary closing conditions.
Funds raised will support the advancement of the company's lead drug candidate, bempikibart, into future clinical trials. Bempikibart is an anti-IL-7Rα antibody being developed for the treatment of alopecia areata and other autoimmune and inflammatory diseases. Q32 Bio aims to re-regulate adaptive immune function with its therapeutic approach.
Morgan Stanley, Jefferies, and Cantor Fitzgerald are acting as joint book-running managers for the offering. Oppenheimer & Co. is also a book-running manager, and H.C. Wainwright & Co. serves as lead manager. The offering was made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission.